Urine thrombomodulin in patients with idiopathic pulmonary fibrosis.

and, like you, we think that some cases require in-hospital monitoring at the beginning of amiodarone therapy. However, we would like to point out that an early variant of amiodarone pulmonary toxicity (albeit not quite as early as in the case we described) can also be seen in patients re¬ ceiving amiodarone doses as low as 100 mg daily. In these cases, reducing the dose would not prevent the occurrence of this complication.